Table 4.
The results of SVR by genotypes and drugs of the patients.
| Genotype | Drugs by Genotype | Ribavirin Use | SVR 24 (%) |
|---|---|---|---|
| Genotype 2 | 6 Sofosbuvir+Ledipasvir | 6 yes; 0 no | 100.00 |
| 24 Sofosbuvir | 22 yes | 90.90 | |
| 2 no | 50.00 | ||
| 5 Sofosbuvir+Daclatasvir | 0 yes; 5 no | 100.00 | |
| Genotype 2 Mean SVR | 91.42 | ||
| Genotype 4 | 9 Sofosbuvir+ Ledipasvir | 5 yes | 100.00 |
| 4 no | 100.00 | ||
| 12 PRO* | 12 yes; 0 no | 100.00 | |
| Genotype 4 Mean SVR | 100.00 | ||
| Genotype 3 | 7 Sofosbuvir+ Ledipasvir | 7 yes; 0 no | 100.00 |
| 1 PROD* | 1 yes; 0 no | 100.00 | |
| 6 Sofosbuvir | 6 yes; 0 no | 100.00 | |
| 27 Sofosbuvir+Daclatasvir | 0 yes; 27 no | 96.29 | |
| Genotype 3 Mean SVR | 97.56 | ||
| Genotype 1b+4 | 3 Sofosbuvir+ Ledipasvir | 0 yes; 3 no | 100.00 |
| Genotype 1b+2+3 | 1 Sofosbuvir+ Ledipasvir | 1 yes; 0 no | 100.00 |
| Overall SVR | 97.63 | ||
*
PROD: Paritaprevir. Ombitasvir. Ritonavir.Dasabuvir; SVR: Sustaied Virological Response